This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nakashima, L. Articles by Swenerton, K. Search for Related Content PubMed Articles by Nakashima, L. Articles by Swenerton, K. Social Bookmarking                         What's this?

Significant hypersensitivity with paclitaxel managed by a 50 hour infusion

Department of Pharmacy, Vancouver Cencer Centre

Oliver Keller, MD, FRCPC

Department of Medical Oncology, Vancouver Cancer Centre

Shelley Speck, RN

Department of Nursing, Vancouver Cancer Centre

Kenneth Swenerton, MD, FRCPC

Department of Gynecological Oncology Affiliation, BC Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia

Paclitaxel is a new antineoplastic agent isolated from the bark of the Western Yew tree. It can be associated with hypersensitivity reactions. Usually these reactions are prevented through the use of a premedication regimen including dexamethasone, diphenhydramine, and cimetidine. Some patients, however, have difficulty tolerating the paclitaxel despite premedication. We report the case of a patient who developed a hypersensitivity reaction to paclitaxel. We were able to administer the paclitaxel by extending the infusion time to ap proximately 50 hours. This strategy could poten tially be used for patients whose hypersensitivity reaction appears rate related.

Key Words: Paclitaxel • hypersensitivity.

Journal of Oncology Pharmacy Practice, Vol. 1, No. 1, 47-50 (1995)
DOI: 10.1177/107815529500100106


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?